Iterum Therapeutics plc (ITRM)
After hours:
| Previous close | 1.5900 |
| Open | 1.6150 |
| Bid | 1.5300 x 200 |
| Ask | 1.5900 x 100 |
| Day's range | 1.5500 - 1.6500 |
| 52-week range | 0.6220 - 2.5000 |
| Volume | |
| Avg. volume | 180,472 |
| Market cap | 25.66M |
| Beta (5Y monthly) | 2.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
GlobeNewswireIterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Monday, May 13, 2024. Management will host a
- GlobeNewswire
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has resubmitte
Insider MonkeyIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]
